Author of

• 17398

  +

  P2.01 - Poster Session with Presenters Present (ID 461)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Biology/Pathology
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17427

    +

    P2.01-029 - Tumor B7-H3 (CD276) Protein Expression, Smoking History, and Survival in Lung Adenocarcinoma Patients (ID 4827)

    14:30 - 14:30  |  Author(s): H. Ninomiya
    • Abstract

    Background:
    Compared with non-smoking counterparts, smoking-associated lung cancers is characterized by a high frequency of somatic mutations, including mutations of DNA repair genes, a high burden of neoantigens, and increased immunogenicity. B7-H3 (also known as CD276) belongs to a family of immune modulators that includes PD-1 and PD-L1 (also known as B7-H1 or CD274). Considering the better response to PD-L1 inhibitors in smokers’ lung cancer, we examined the prognostic interaction of tumor B7-H3 expression with smoking history in lung adenocarcinoma patients.
    
    Methods:
    Using tissue microarrays of consecutive 270 cases of lung adenocarcinoma, we evaluated tumor B7-H3 expression by immunohistochemistry. We examined the prognostic association of B7-H3 expression in strata of smoking history, using Cox proportional hazards regression analysis and the log-rank test. Additionally, we used logistic regression analysis to examine the correlations between B7-H3 expression levels and clinicopathological/molecular features of lung adenocarcinoma.
    
    Results:
    The association of B7-H3 expression with survival significantly indeed differed by smoking history (Pinteraction=0.014); B7-H3 high-expression was associated with inferior survival in moderate/heavy-smoking patients (smoking index [SI]≥400) (hazard ratio [HR]=3.07, 95% confidence interval [CI]=1.74-5.49, P=0.0001) (log-rank test: P<0.0001), but not in non/light-smoking patients (SI<400) (HR=2.24, 95% CI=0.63-1.96, P=0.64) (log-rank: P=0.64). High B7-H3 expression was associated with smoking patients (univariable odds ratio [OR]=2.63, 95 % CI=1.51-4.65, P=0.0005) and independently associated with EGFR wild-type status (multivariable OR=2.80, 95% CI=1.38-5.84, P=0.0042).
    
    Conclusion:
    We demonstrated that the prognostic association of B7-H3 expression indeed differed according to smoking history. The current study also showed significant association of high B7-H3 expression with EGFR wild-type and smoking patients, indicating the potential effectiveness of anti-B7-H3 therapy for EGFR wild-type or smokers’ lung adenocarcinoma.